Express Scripts Holding Co (ESRX)

ESRX (NASDAQ:Health Services) EQUITY
neg -0.17
Today's Range: 69.24 - 72.03 | ESRX Avg Daily Volume: 3,350,600
Last Update: 10/26/16 - 1:16 PM EDT
Volume: 2,951,734
YTD Performance: -19.84%
Open: $72.03
Previous Close: $70.07
52 Week Range: $65.55 - $94.22
Oustanding Shares: 630,219,000
Market Cap: 43,989,286,200
6-Month Chart
TheStreet Ratings Grade for ESRX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 7 8
Moderate Buy 0 0 0 0
Hold 9 8 8 8
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.33 2.37 2.37 2.29
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 17.32
Price Earnings Comparisons:
ESRX Sector Avg. S&P 500
17.32 19.60 29.60
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-9.46% -17.67% 15.10%
Revenue 0.90 0.10 0.03
Net Income 22.80 0.80 0.22
EPS 34.80 1.00 0.26
Earnings for ESRX:
Revenue 101.75B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $1.85 $1.35 $6.37 $6.89
Number of Analysts 13 8 16 16
High Estimate $1.88 $1.38 $6.40 $7.04
Low Estimate $1.81 $1.27 $6.33 $6.75
Prior Year $1.56 $1.22 $5.53 $6.37
Growth Rate (Year over Year) 18.49% 10.45% 15.17% 8.16%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

Gilead Is a Buying Opportunity Real Money Pro($)

Its hepatitis C drug is better; the stock trades at a discount.
Here's the best way to play them.
Stocks that do well when the economy rises are shining.

In Defense of Gilead Sciences Real Money Pro($)

It has a great long-term future.
It might be good for consumers, but not for the stock.
Sep 11, 2014 | 6:50 AM EDT
ESRX was downgraded from Buy to Neutral, Goldman Sachs said. $75 price target. Core business is facing fading growth drivers.

Stick With What Is Working Real Money Pro($)

Here are a few stocks I have made solid calls on recently that have moved up.
Jul 30, 2014 | 8:16 AM EDT
ESRX price target lowered from $86 to $80, Jefferies said. Buy rating. Risk of incremental contract turnover.
Jul 28, 2014 | 8:19 AM EDT
ESRX reduced its number, UBS said. Lack of major generic launches and generic inflation headwinds. $82 price target and Buy rating.&nbs...
Using the bull put spread in times of volatility.

Columnist Conversations

Merck had a nice earnings beat on Tuesday which was accompanied by an earlier than expected FDA approval on Ke...
For years Apple was accused of under promise, over deliver --- UPOD as Jim Cramer likes to call it.  Whil...
Market down across the board, as less than optimistic outlook from Apple (AAPL) dampens investor enthusiasm in...
This morning United Technologies reported GAAP eps of $1.74 up 8% from a year ago. In Q3, sales were up by 5% ...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.